Mitralign

Mitralign, Inc. is the valve repair company with the only direct transcatheter annuloplasty system designed to treat both functional mitral regurgitation and tricuspid regurgitation. We are a venture-backed, medical innovation company located near Boston, Massachusetts, USA. We’ve developed an innovative therapy for the reduction of functional mitral regurgitation (FMR), a life-threatening cardiac condition affecting four million people in the U.S. alone1. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation (MR ≥ 3+) for annular reduction through tissue plication. In addition, we have developed an approach to treating tricuspid valve regurgitation with a delivery system designed for transcatheter tricuspid valve repair. Our unique system provides a new solution for interventional cardiologists and their patients.
Type
Private
HQ
Tewksbury, US
Founded
2003
Employees
51 (est)
Mitralign was founded in 2003 and is headquartered in Tewksbury, US

Key People at Mitralign

Rick Geoffrion

Rick Geoffrion

CEO
Adam Groothuis

Adam Groothuis

Vice President
Richard J. Omilanowicz

Richard J. Omilanowicz

COO/CFO

Mitralign Locations

Tewksbury, US

Mitralign Metrics

Mitralign Summary

Founding Date

2003

Total Funding

$142 M

Latest funding size

$39.8 M

Time since last funding

8 months

Investors

We estimate that Mitralign's latest funding round in May 2016 was $39.8 M. In total, Mitralign has raised $142 M

Mitralign Online Presence

Mitralign Company Life